Otonomy Inc
F:7OT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HKC International Holdings Ltd
HKEX:248
|
HK |
|
G
|
GMR Power and Urban Infra Ltd
NSE:GMRP&UI
|
IN |
|
T
|
Tianjin Port Co Ltd
SSE:600717
|
CN |
|
B
|
Bed Bath & Beyond Inc
LSE:0HMI
|
US |
|
Golden Eagle Retail Group Ltd
HKEX:3308
|
CN |
|
G
|
Gezinomi Seyahat Turizm Ticaret AS
IST:GZNMI.E
|
TR |
|
A
|
Axyz Co Ltd
TSE:1381
|
JP |
Otonomy Inc
Total Current Liabilities
Otonomy Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Otonomy Inc
F:7OT
|
Total Current Liabilities
$25.3m
|
CAGR 3-Years
33%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Current Liabilities
$54.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Current Liabilities
$23.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Current Liabilities
$37B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Current Liabilities
$28.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Current Liabilities
$35.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
Otonomy Inc
Glance View
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
See Also
What is Otonomy Inc's Total Current Liabilities?
Total Current Liabilities
25.3m
USD
Based on the financial report for Sep 30, 2022, Otonomy Inc's Total Current Liabilities amounts to 25.3m USD.
What is Otonomy Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
19%
Over the last year, the Total Current Liabilities growth was 159%. The average annual Total Current Liabilities growth rates for Otonomy Inc have been 33% over the past three years , 19% over the past five years .
